Results 21 to 30 of about 238,162 (269)

Independent effects of white matter hyperintensities on cognitive, neuropsychiatric, and functional decline: a longitudinal investigation using the National Alzheimer’s Coordinating Center Uniform Data Set

Alzheimer’s Research & Therapy, 2019
Background Longitudinal investigations are needed to improve understanding of the contributions of cerebral small vessel disease to the clinical manifestation of Alzheimer’s disease, particularly in the early disease stages.
Christian Puzo, Caroline Labriola, Michael A. Sugarman, Yorghos Tripodis, Brett Martin, Joseph N. Palmisano, Eric G. Steinberg, Thor D. Stein, Neil W. Kowall, Ann C. McKee, Jesse Mez, Ronald J. Killiany, Robert A. Stern, Michael L. Alosco   +13 more
doaj   +1 more source

Focal amyloid and asymmetric tau in an imaging-to-autopsy case of clinical primary progressive aphasia with Alzheimer disease neuropathology

Acta Neuropathologica Communications, 2022
Quantification of in vivo amyloid and tau PET imaging relationships with postmortem measurements are critical for validating the sensitivity and specificity imaging biomarkers across clinical phenotypes with Alzheimer disease neuropathologic change (ADNC)
Adam Martersteck, Ivan Ayala, Daniel T. Ohm, Callen Spencer, Christina Coventry, Sandra Weintraub, Eileen H. Bigio, M. -Marsel Mesulam, Changiz Geula, Emily Rogalski   +9 more
doaj   +1 more source

MOESM1 of Patterns of Chinese medicine use in prescriptions for treating Alzheimerâ s disease in Taiwan

, 2016
Additional file 1. The approval Letter from Taipei City Hospital Institutional Review Board.
Shun-Ku Lin, Sui-Hing Yan, Jung-Nien Lai, Tung-Hu Tsai   +3 more
openaire   +1 more source

Communication Bridge™-2 (CB2): an NIH Stage 2 randomized control trial of a speech-language intervention for communication impairments in individuals with mild to moderate primary progressive aphasia

Trials, 2022
Background Primary progressive aphasia (PPA) is a clinical dementia syndrome. Impairments in language (speaking, reading, writing, and understanding) are the primary and persistent symptoms.
Angela C. Roberts, Alfred W. Rademaker, Elizabeth Ann Salley, Aimee Mooney, Darby Morhardt, Melanie Fried-Oken, Sandra Weintraub, Marsel Mesulam, Emily Rogalski   +8 more
doaj   +1 more source

MOESM2 of Patterns of Chinese medicine use in prescriptions for treating Alzheimerâ s disease in Taiwan

, 2016
Additional file 2. The approval Letter from National Institutes of Health.
Shun-Ku Lin, Sui-Hing Yan, Jung-Nien Lai, Tung-Hu Tsai   +3 more
openaire   +1 more source

Longitudinal chemokine profile expression in a blood-brain barrier model from Alzheimer transgenic versus wild-type mice

Journal of Neuroinflammation, 2018
Background Alzheimer’s disease is widely described since the discovery of histopathological lesions in Mrs. Auguste Deter in 1906. However to date, there is no effective treatment to deal with the many cellular and molecular alterations.
J. Vérité, T. Janet, D. Chassaing, B. Fauconneau, H. Rabeony, G. Page   +5 more
doaj   +1 more source

Potential therapeutic target for aging and age-related neurodegenerative diseases: the role of acid sphingomyelinase

Experimental and Molecular Medicine, 2020
Age-related neurodegenerative diseases: role of enzyme crucial to membrane function Targeting a critical enzyme involved in the metabolism of cellular membrane molecules could help treat age-related neurodegenerative diseases.
Min Hee Park, Hee Kyung Jin, Jae-sung Bae   +2 more
doaj   +1 more source

Additional file 1: of Cost-effectiveness of cerebrospinal biomarkers for the diagnosis of Alzheimerâ s disease

, 2017
Cost-effectiveness of cerebrospinal biomarkers for Alzheimerâ s diagnosis: supplemental Methods, Results, figures and tables as referenced in the text. (DOCX 91 kb)
Lee, Spencer, Sposato, Luciano, Hachinski, Vladimir, Cipriano, Lauren   +3 more
openaire   +1 more source

Microbiome−host proteostasis crosstalk—An emerging perspective on mechanisms and interventions toward healthy longevity

FEBS Letters, EarlyView.
Proteostasis and the gut microbiota play a key role in shaping host physiology. Microbiota‐derived metabolites, vitamins, and RNA modulate host proteostasis. Findings from model systems, including C. elegans, indicate microbes can either stabilize or disrupt host proteostasis.
Abhishek Anil Dubey, Maria Ermolaeva
wiley   +1 more source

Brain autopsies of critically ill COVID-19 patients demonstrate heterogeneous profile of acute vascular injury, inflammation and age-linked chronic brain diseases

Acta Neuropathologica Communications, 2022
Background This study examined neuropathological findings of patients who died following hospitalization in an intensive care unit with SARS-CoV-2. Methods Data originate from 20 decedents who underwent brain autopsy followed by ex-vivo imaging and ...
Sonal Agrawal, Jose M. Farfel, Konstantinos Arfanakis, Lena Al-Harthi, Tanner Shull, Tara L. Teppen, Arnold M. Evia, Mayur B. Patel, E. Wesley Ely, Sue. E. Leurgans, David A. Bennett, Rupal Mehta, Julie A. Schneider   +12 more
doaj   +1 more source